Overview Navitoclax (ABT-263) is a small-molecule BH3 mimetic — a drug that mimics the BH3 (Bcl-2 homology domain 3) domain of pro-apoptotic proteins to inhibit anti-apoptotic BCL-2 family members (BCL-2, BCL-XL, BCL-W). It was developed by AbbVie as an oncology agent targeting BCL-2-dependent…
In the full monograph
- What it is, and how it works
- What the evidence shows — randomized trials, observational data, animal studies, graded and cited
- Dose, form, and timing
- What to expect, and how soon
- Who should be careful, and what to check first
- The verdict
MEMBERS
Read the full monograph
Members get every monograph in the library, the research assistant, and the stack tracker — with a 30-day money-back guarantee. Not ready? Start free with the Proven Supplements Starter Guide.